Ovarian endometrioid adenocarcinoma

Summary

Ovarian endometrioid adenocarcinoma (MONDO:0006335) is a disease with 1 cohort gene (2 GWAS associations across 1 studies) and 70 clinical trials. Molecularly, BRCA1 W1815X confers sensitivity to Olaparib in Endometrioid Ovary Carcinoma (CIViC Level D). Top therapeutic interventions include paclitaxel, topotecan, and olaparib.

At a glance

• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Cohort genes: 1
• GWAS associations: 2
• Clinical trials: 70
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.81	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.51	Korea, Republic of	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian endometrioid adenocarcinoma
Mondo ID	MONDO:0006335
EFO	EFO:1000416
Orphanet	454723
DOID	DOID:5828
NCIT	C7979
SNOMED CT	254852002
UMLS	C0346163
MedGen	91087
GARD	0021893
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: endometrioid adenocarcinoma of ovary · endometrioid adenocarcinoma of the ovary · endometrioid cancer of ovary · endometrioid cancer of the ovary · endometrioid carcinoma of ovary · endometrioid carcinoma of the ovary · endometrioid ovarian cancer · endometrioid ovary carcinoma · endometrium adenocarcinoma of ovary · ovarian endometrioid adenocarcinoma · ovarian endometrioid cancer · ovarian endometrioid carcinoma · ovary endometrium adenocarcinoma

Data availability: 2 GWAS associations (1 study) · 116 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › ovarian adenocarcinoma › ovarian endometrioid adenocarcinoma

Related subtypes (6): ovarian cystadenocarcinoma, rete ovarii adenocarcinoma, Krukenberg carcinoma, ovarian serous adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian clear cell adenocarcinoma

Subtypes (1): ovarian endometrioid adenocarcinoma with squamous differentiation

Genetics & variants

GWAS landscape

2 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr5:66125696	2e-06		T	0.13
chr9:16914716	8e-06		A	0.16

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90244170	Dareng EO	2024	2,877	105,724	Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	2
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
unknown	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr5:66125696				0.49			2e-06	Tier 4: intronic/intergenic
chr9:16914716				0.205			8e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA1	9,064

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA1	P38398	33

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 59. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective DNA double strand break response due to BRCA1 loss of function	1	5710.0×	0.005	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	5710.0×	0.005	BRCA1
Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	1	1631.4×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	951.7×	0.009	BRCA1
Diseases of DNA Double-Strand Break Repair	1	815.7×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	815.7×	0.009	BRCA1
Resolution of D-Loop Structures	1	634.4×	0.009	BRCA1
Diseases of DNA repair	1	571.0×	0.009	BRCA1
DNA Double Strand Break Response	1	475.8×	0.009	BRCA1
Impaired BRCA2 binding to PALB2	1	456.8×	0.009	BRCA1
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	423.0×	0.009	BRCA1
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	423.0×	0.009	BRCA1
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	423.0×	0.009	BRCA1
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	393.8×	0.009	BRCA1
Homologous DNA Pairing and Strand Exchange	1	380.7×	0.009	BRCA1
Homology Directed Repair	1	308.6×	0.009	BRCA1
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	308.6×	0.009	BRCA1
Impaired BRCA2 binding to RAD51	1	308.6×	0.009	BRCA1
Metalloprotease DUBs	1	300.5×	0.009	BRCA1
Resolution of D-loop Structures through Holliday Junction Intermediates	1	300.5×	0.009	BRCA1
HDR through Single Strand Annealing (SSA)	1	292.8×	0.009	BRCA1
Transcriptional Regulation by E2F6	1	292.8×	0.009	BRCA1
Meiosis	1	285.5×	0.009	BRCA1
Presynaptic phase of homologous DNA pairing and strand exchange	1	271.9×	0.009	BRCA1
DNA Double-Strand Break Repair	1	248.3×	0.010	BRCA1
Reproduction	1	190.3×	0.011	BRCA1
HDR through Homologous Recombination (HRR)	1	190.3×	0.011	BRCA1
TP53 Regulates Transcription of DNA Repair Genes	1	181.3×	0.011	BRCA1
MITF-M-dependent gene expression	1	181.3×	0.011	BRCA1
SUMO E3 ligases SUMOylate target proteins	1	178.4×	0.011	BRCA1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular response to indole-3-methanol	1	3370.4×	0.004	BRCA1
chordate embryonic development	1	2808.7×	0.004	BRCA1
negative regulation of centriole replication	1	2407.4×	0.004	BRCA1
DNA strand resection involved in replication fork processing	1	2106.5×	0.004	BRCA1
DNA damage tolerance	1	1685.2×	0.004	BRCA1
homologous recombination	1	1404.3×	0.004	BRCA1
negative regulation of intracellular estrogen receptor signaling pathway	1	1123.5×	0.004	BRCA1
regulation of DNA damage checkpoint	1	1123.5×	0.004	BRCA1
negative regulation of gene expression via chromosomal CpG island methylation	1	1053.2×	0.004	BRCA1
protein K6-linked ubiquitination	1	991.3×	0.004	BRCA1
random inactivation of X chromosome	1	936.2×	0.004	BRCA1
negative regulation of reactive oxygen species metabolic process	1	936.2×	0.004	BRCA1
negative regulation of fatty acid biosynthetic process	1	887.0×	0.004	BRCA1
mitotic G2/M transition checkpoint	1	802.5×	0.004	BRCA1
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	1	581.1×	0.005	BRCA1
positive regulation of vascular endothelial growth factor production	1	495.6×	0.005	BRCA1
mitotic G2 DNA damage checkpoint signaling	1	443.5×	0.005	BRCA1
response to ionizing radiation	1	411.0×	0.005	BRCA1
cellular response to ionizing radiation	1	411.0×	0.005	BRCA1
positive regulation of DNA repair	1	358.6×	0.006	BRCA1
fatty acid biosynthetic process	1	351.1×	0.006	BRCA1
centrosome cycle	1	337.0×	0.006	BRCA1
intrinsic apoptotic signaling pathway in response to DNA damage	1	324.1×	0.006	BRCA1
negative regulation of cell cycle	1	290.6×	0.006	BRCA1
regulation of DNA repair	1	276.3×	0.006	BRCA1
protein autoubiquitination	1	234.1×	0.007	BRCA1
double-strand break repair	1	203.0×	0.008	BRCA1
chromosome segregation	1	173.7×	0.009	BRCA1
cellular response to tumor necrosis factor	1	163.6×	0.009	BRCA1
double-strand break repair via homologous recombination	1	156.0×	0.009	BRCA1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA1	12	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRCA1	13	Binding:9, Functional:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

12 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	BRCA1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 70.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	24
PHASE1	22
PHASE3	11
PHASE1/PHASE2	4
Not specified	4
EARLY_PHASE1	3
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00565851	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT01167712	PHASE3	ACTIVE_NOT_RECRUITING	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT02446600	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02839707	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04111978	PHASE3	RECRUITING	MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04575935	PHASE3	RECRUITING	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT05281471	PHASE3	RECRUITING	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician’s Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT00108745	PHASE3	UNKNOWN	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00262847	PHASE3	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00719303	PHASE3	UNKNOWN	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00951496	PHASE3	COMPLETED	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT01116648	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
NCT02068794	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT02101775	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03348631	PHASE2	ACTIVE_NOT_RECRUITING	Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03587311	PHASE2	ACTIVE_NOT_RECRUITING	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04034927	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04739800	PHASE2	ACTIVE_NOT_RECRUITING	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04919629	PHASE2	RECRUITING	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT05231122	PHASE2	RECRUITING	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05920798	PHASE1/PHASE2	RECRUITING	Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT06639074	PHASE2	RECRUITING	Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT06690775	PHASE2	RECRUITING	CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT00004221	PHASE2	TERMINATED	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
NCT00059787	PHASE2	COMPLETED	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00466960	PHASE2	COMPLETED	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
NCT00888615	PHASE2	COMPLETED	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00939809	PHASE2	COMPLETED	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00993616	PHASE2	COMPLETED	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
NCT01010126	PHASE2	COMPLETED	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
NCT01097746	PHASE2	COMPLETED	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02122185	PHASE2	COMPLETED	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02283658	PHASE2	COMPLETED	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT02364713	PHASE2	TERMINATED	MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT02713386	PHASE1/PHASE2	COMPLETED	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318	PHASE2	COMPLETED	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02923739	PHASE2	TERMINATED	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03648489	PHASE2	COMPLETED	Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACLITAXEL	4	26
TOPOTECAN	4	5
OLAPARIB	4	3
GEMCITABINE	4	2
ATEZOLIZUMAB	4	1
BELINOSTAT	4	1
BEVACIZUMAB	4	1
COPANLISIB HYDROCHLORIDE	4	1
DENILEUKIN DIFTITOX	4	1
DIPHTHERIA TOXOID	4	1
ERLOTINIB	4	1
GRANISETRON	4	1
METFORMIN	4	1
PEGCETACOPLAN	4	1
RUXOLITINIB PHOSPHATE	4	1
TAZEMETOSTAT	4	1
TEMSIROLIMUS	4	1
TETANUS TOXOID	4	1
CEDIRANIB	3	6
VELIPARIB	3	4
PACLITAXEL POLIGLUMEX	3	2
ACETYLCARNITINE	3	1
ELESCLOMOL	3	1
EMACTUZUMAB	3	1
ENTINOSTAT	3	1
IPATASERTIB	3	1
OLVIMULOGENE NANIVACIREPVEC	3	1
ADAVOSERTIB	2	1
ANETUMAB RAVTANSINE	2	1
SAPANISERTIB	2	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
BRCA1 W1815X	Olaparib	Sensitivity/Response	CIViC D	EID4623